about
Genetic and Epigenetic Alterations in Bladder CancerElevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaEvaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded TissuesComprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model.Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivoThe role of genomics in the management of advanced bladder cancer.Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?Targeted therapies in bladder cancer: an overview of in vivo research.Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancerAndrogen receptor activation: a prospective therapeutic target for bladder cancer?The evolving genomic landscape of urothelial carcinoma.Fibroblast Growth Factor Receptor 3 (FGF-R3): A Promising Therapeutic Target for the Treatment of Bladder Cancer.Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer
P2860
Q28074732-16F91EC8-9D4D-40DD-B3BA-7A65F2C63A73Q28084715-8F19B72B-D47C-4AAF-9D83-77E6E722856CQ30489412-E078E791-9373-4BD3-9F91-B020DBD24A9EQ33698804-ACDB57A5-B580-4CDF-81D4-516273B53C8CQ35864528-345D7691-DFF3-447D-AC1A-1028B7C25F6AQ35998718-C1705252-1DEE-44DE-9BAE-3B68CD8C0395Q36547894-16764ABC-DA2A-4504-9391-B1F0AB072788Q37012561-D3AD445C-CAAD-42B9-90FA-FAFEB0FB85D1Q37063904-3B5E7784-E765-48DF-BB95-EFEA4EC6A03FQ37295668-FC02691A-72D5-4BE3-8ADC-8D52BFDD3B06Q38342992-3A7D9ED7-D765-4AC0-AB41-67E23041F391Q38508249-B8D5871A-E2D2-46AC-97CB-8463CA50952FQ38590471-315FB444-30AC-427E-A8E0-47BA09169E3BQ38764114-3686E0E5-97AA-40B7-9E8B-1C22144255A8Q39033724-F3F5258E-CBDA-4E68-8A82-8602B9AC780DQ39124491-5AEF1905-ACFD-4780-99A4-2507CE04CE73Q40151416-43679B8B-07B5-45F0-9C14-4A52A0BB3676Q48898011-FE5136A3-DEFE-44E5-AC64-9868EE8500EBQ50049202-D35B417E-231D-4E9F-895F-B9D9FCB838F5Q58768900-B0AE7267-A9D1-432C-B194-261A6151E30B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeted therapies in urothelial carcinoma.
@en
type
label
Targeted therapies in urothelial carcinoma.
@en
prefLabel
Targeted therapies in urothelial carcinoma.
@en
P1476
Targeted therapies in urothelial carcinoma
@en
P2093
Andrea B Apolo
Monalisa Ghosh
P304
P356
10.1097/CCO.0000000000000064
P577
2014-05-01T00:00:00Z